Supernus Pharmaceuticals Inc. (SUPN) Upgraded to “Buy” at Zacks Investment Research
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage presently has a $26.00 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price target indicates a potential upside of 10.54% from the company’s previous close.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
SUPN has been the topic of a number of other research reports. Piper Jaffray Cos. downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research report on Monday, July 18th. Jefferies Group reiterated a “buy” rating and set a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Finally, Northland Securities downgraded shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research report on Monday, July 18th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $25.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 2.04% on Wednesday, reaching $24.00. 279,316 shares of the company were exchanged. The stock has a market capitalization of $1.19 billion, a P/E ratio of 48.98 and a beta of 1.73. The company’s 50-day moving average price is $23.37 and its 200-day moving average price is $19.92. Supernus Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $26.84.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. The firm had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 EPS. Equities research analysts anticipate that Supernus Pharmaceuticals will post $0.68 earnings per share for the current fiscal year.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now owns 3,616 shares in the company, valued at approximately $90,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.10% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its stake in shares of Supernus Pharmaceuticals by 1.1% in the first quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock worth $43,112,000 after buying an additional 31,238 shares during the period. Alps Advisors Inc. raised its stake in Supernus Pharmaceuticals by 26.2% in the second quarter. Alps Advisors Inc. now owns 69,426 shares of the specialty pharmaceutical company’s stock valued at $1,414,000 after buying an additional 14,407 shares during the last quarter. California State Teachers Retirement System raised its stake in Supernus Pharmaceuticals by 35.2% in the second quarter. California State Teachers Retirement System now owns 98,380 shares of the specialty pharmaceutical company’s stock valued at $2,004,000 after buying an additional 25,597 shares during the last quarter. Nicholas Investment Partners LP purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at about $1,990,000. Finally, Granahan Investment Management Inc. MA purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at about $5,945,000. Institutional investors and hedge funds own 94.66% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.